Fenbendazole & Cancer

Antiparasitic Cancer Therapy

Fenbendazole & Cancer's avatar
Fenbendazole & Cancer
Nov 16, 2026
∙ Paid

Several repurposed antiparasitic agents have demonstrated preclinical activity targeting cancer stem cells (CSCs) and tumor-initiating populations by disrupting self-renewal transcription factors, developmental signaling cascades, and cellular bioenergetics:

User's avatar

Continue reading this post for free, courtesy of Fenbendazole & Cancer.

Or purchase a paid subscription.
© 2026 Fenbendazole & Cancer · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.